Brought to you by 
BL&H and Biotech-IgG to sell OncAlert risk test for Vigilant
23 Nov 2015
Executive Summary
Vigilant Biosciences Inc. signed its first marketing partners for the OncAlert oral cancer risk assessment system. BL&H Co. Ltd. gets exclusive rights for five years in Korea, while Biotech-IgG AB has exclusive rights in Denmark, Norway, and Sweden for three years.
Deal Industry
- In Vitro Diagnostics
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
- Saliva-based Testing
Deal Status
- Final
Deal Type
-
Alliance
- Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
BL&H and Biotech-IgG to sell OncAlert risk test for Vigilant
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice